SLC39A6 and neoplasm: (1998) previously reported that in ER + tumours, SLC39A6 was associated with a variable response to endocrine therapy [17].This study indicates SLC39A6 is associated with a longer survival in ER + BC patients who did not receive hormone therapy more than who were given such treatment.